MaaT Pharma Receives Negative CHMP Trend Vote for MaaT013 (Xervyteg®) Following Re-Examination for its Conditional Marketing Authorization Application in Europe
Regulatory News:MaaT Pharma (EURONEXT: MAAT — the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies™ (MET) dedicated to enhancing survival for patients with cancer through immune modulation, today announced that it has been informed…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.